deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT00827489

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Healthy Subjects
Interventions HTC-867 Placebo
Updated 6 times since 2017 Last updated: Sep 1, 2009 Started: Jan 31, 2009 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Wyeth is now a wholly owned subsidiary of Pfizer

See all terminations from Wyeth is now a wholly owned subsidiary of Pfizer

Other Healthy Subjects trials with similar outcome

Browse all Healthy Subjects trials

Listed as NCT00827489, this PHASE1 trial focuses on Healthy Subjects and remains terminated or withdrawn. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations